A Phase 4 interventional study of Voltaren Gel in Pain, sponsored by HALEON. Completed at 8 sites in 2 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by HALEON · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in Pain with a site in Poland — 9 open to participants now, 9 under way, none of them phase 3. Pain · Poland.
Among the 97 studies in Pain with a site in Poland, this one is the 47th largest by enrollment of the 89 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 4, and was the 86th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →9 of the 97 studies in Pain with a site in Poland are open now. Recruiting first, the newest first:
Jagiellonian University · Sites in Poland
Ages 18–80
Teleflex · Sites in Poland, United States, France and 1 more country
Ages 18–80
Medical University of Silesia · Sites in Poland
Ages 18–75
Poznan University of Physical Education · Sites in Poland
Ages 18–90 · Healthy volunteers
KeyBioscience AG · Sites in Poland, Czechia, Denmark and 3 more countries
Ages 45+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 22 · Phase 3 37 · Phase 4 4
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 200 across the 89 interventional studies, 200 across the 7 observational. Of the 81 that completed or were terminated, 32 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 97 have an industry lead sponsor. The 10 most frequent:
HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
HALEON has 9 studies filed under Pain — fewer than ten, so there is no comparison to draw.
5 of the studies in Pain with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06833749KeyBioscience AGEfficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | 2026-11 |
| NCT04214561Wroclaw Medical UniversityRelationship Between Selected Parameters and Bruxism | 2026-12 |
| NCT06975345Wroclaw University of Health and Sport SciencesEffects of a Protocol of Hip Flexor Stretching on Chronic Mechanical, Non-specific LBP. | 2026-12-31 |
| NCT07434427Medical University of SilesiaComparison of the Efficacy and Safety of Intravenous Buprenorphine Administered Via PCA System Versus Oxycodone in the Management of Postoperative Pain After Video-Assisted Thoracoscopic Surgery | 2027-05 |
| NCT07831967Medical University of GdanskPerfusion Index Variability During Epidural Labor Analgesia | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 97 studies in Pain with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate how topical diclofenac use can improve functional mobility and physical activity primarily, as well as other quality-of-life (QoL) parameters such as sleep, mood, and engagement in daily activities in participants with knee OA.
This prospective open-label, single-arm, multi-country (United States [US] and European Union [EU]) real-world evidence study will be conducted in a hybrid form and will focus on assessing the impact of Voltaren Gel on functional mobility and QoL in individuals with mild/nonserious OA of the knee. Participants will be required to be physically present at the study site for screening, end of baseline and end of study visits. The remaining treatment will be conducted in a remote manner (for example, at home) to observe the real-world usage of Voltaren Gel. This study will utilize a research-grade validated wearable device: Actigraph, to accurately measure objective changes in functional mobility. Sufficient participants will be screened to enroll approximately 195 participants to ensure that around 147 of these participants will successfully complete the entire study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will use Voltaren Gel topically, applied daily as per label and leaflet instructions for up to 21 days. Participants will be instructed to wear Actigraph device on the wrist as per label, leaflet or site-specific instructions post training throughout the day for up to 21 days.
Drug: Voltaren Gel
Diclofenac sodium gel in 3 different concentrations as- Diclofenac sodium 1%, 1.16% and 2.32% whichever was available in the given region.
Change From Baseline in the Average Minutes of Moderate and Vigorous Physical Activity (MVPA) at Week 1
The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A mixed model with repeated measures (MMRM) was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 1. Baseline value was calculated as the sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement. Modified Intent-To-Treat (mITT) population included all participants who met the inclusion/exclusion criteria, who used study product at least once and had data from at least one post Baseline quality of life (QoL) questionnaire to support at least one of the secondary endpoint assessments.
Time frame: Baseline and Week 1
Change From Baseline in the Average Minutes of MVPA at Week 2
The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A MMRM was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 2. Baseline value was calculated as sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.
Time frame: Baseline and Week 2
Change From Baseline in the Average Minutes of MVPA at Week 3
The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A MMRM was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 3. Baseline value was calculated as sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.
Time frame: Baseline and Week 3
Change From Baseline in Daily Average Number of Steps Taken at Weeks 1, 2 and 3
Daily average number of steps taken were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on functional mobility. MMRM was used to analyse the change from Baseline in daily average number of steps taken. Change from Baseline was calculated by subtracting the average number of steps taken at Baseline from the average number of steps taken at each indicated post-Baseline timepoint. Baseline value was calculated as the sum of steps taken over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
Change From Baseline in Ratio of Sedentary/Non-sedentary Time at Weeks 1, 2 and 3
Sedentary/non-sedentary time was measured using a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on functional mobility. Ratio of sedentary/non-sedentary time was calculated as = Total number of minutes defined as sedentary behaviour divided by Total number of non-sedentary behaviour minutes where number of non-sedentary behaviour minutes in the day was derived as the sum of light activity and MVPA. Change from Baseline was calculated by subtracting the Baseline ratio of sedentary/non-sedentary time from the ratio at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
Change From Baseline in Gait Assessed Through Speed and Step Irregularity Measured Via Cadence at Weeks 1, 2 and 3
Gait was assessed through speed and step irregularity measured via cadence using a connected activity tracker (Actigraph device) worn by the participants. Change from Baseline was calculated as by subtracting the average cadence at Baseline from the cadence at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
Change From Baseline in Gait Assessed Through Speed and Step Irregularity Measured Via Gait Speed at Weeks 1, 2 and 3
Gait was assessed through speed and step irregularity measured via gait speed using a connected activity tracker (Actigraph device) worn by the participants. Change from Baseline was calculated by subtracting the average gait speed at Baseline from the Average gait speed at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
Change From Baseline in Indices of Morning Stiffness Assessed Through Levels of Mobility 30 Minutes Post-wake at Weeks 1, 2 and 3
Indices of morning stiffness were assessed through levels of mobility 30 minutes post-wake. Functional mobility was measured through a connected activity tracker (Actigraph device) worn by the participants. Daily morning stiffness 30 minutes post-wake was defined as the total vector magnitude counts from Actigraph device 30 minutes post-wake. Change from Baseline was calculated as = (Average morning stiffness 30 minutes post-wake at each indicated post-Baseline timepoint minus Average Baseline morning stiffness 30 minutes post-wake). Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
Change From Baseline in Indices of Morning Stiffness Assessed Through Levels of Mobility 60 Minutes Post-wake at Weeks 1, 2 and 3
Indices of morning stiffness were assessed through levels of mobility 60 minutes post-wake. Functional mobility was measured through a connected activity tracker (Actigraph device) worn by the participants. Daily morning stiffness 60 minutes post-wake was defined as the total vector magnitude counts from Actigraph device 60 minutes post-wake. Change from Baseline was calculated as = (Average morning stiffness 60 minutes post-wake at each indicated post-Baseline timepoint minus Average Baseline morning stiffness 30 minutes post-wake). Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
Change From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Physical Function Subscale Score at Week 1, 2 and 3
Participants completed the WOMAC questionnaire daily using eDiary. The WOMAC questionnaire consisted of 24 questions categorised in 3 subscales - Pain, Stiffness, Physical function. The physical function subscale consisted of 17 questions related to level of difficulty in performing functions, on average, during the last 48 hours scored on a 5-point Likert scale with scores ranging from 0 to 4, where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. Total WOMAC physical function subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items)\*1.47. Higher scores indicated more difficulty in performing physical functions. Change from Baseline was calculated by subtracting the normalized WOMAC subscale score at Baseline from the normalized WOMAC subscale score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
MVPA on Each Day of the Study
The average minutes of MVPA on each day were measured through a connected activity tracker (Actigraph device) worn by the participants to assess the functional mobility. Baseline was calculated as the average of MVPA values collected during the Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0.
Time frame: Baseline up to Day 21
WOMAC Physical Function Subscale Score at Weeks 1, 2 and 3
Physical function subscale score of the WOMAC questionnaire was used to study participant's perceived ability to exercise more regularly. It consisted of 17 questions related to the level of difficulty in performing functions, on average, during the last 48 hours scored on a 5-point Likert scale with scores ranging from 0 to 4, daily using eDiary where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. Total WOMAC physical function subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items)\*1.47. Higher scores indicated more difficulty in performing physical functions.
Time frame: Week 1, Week 2 and Week 3
Change From Baseline in Self-reported Pain Intensity Assessed Through Numeric Rating Scale (NRS) at Weeks 1, 2 and 3
Participants rated the pain intensity experienced by them daily within the eDiary, using NRS. NRS is an 11-point scale with scores ranging from 0 to 10 where score 0 = no pain, 1 = slight pain, 2-3 = mild pain, 4-6 = moderate pain, 7 = severe pain, 8 to 9 = extreme pain, 10=pain as bad as it could be. Higher scores indicated greater pain intensity. Change from Baseline was calculated by subtracting the Baseline NRS score from the NRS score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
Change From Baseline in the WOMAC Total Score at Weeks 1, 2 and 3
Participants completed the WOMAC questionnaire daily. The WOMAC questionnaire consisted of 24 questions each scored on a 5-point scale: 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The WOMAC questionnaire was categorized in 3 subscales - Pain (5 questions, score ranges 0-20), Stiffness (2 questions, score ranges 0-8), Physical function (17 questions, score ranges 0-68). Each subscale score was normalized on a 0 to 100 scale calculated as: Pain subscale score= (sum of raw score items in dimension)\*5; Stiffness subscale score= (sum of raw score items in dimension)\*12.5; Physical function subscale score= (sum of raw score items in dimension)\*1.47. WOMAC Total score = sum of the 3 normalized WOMAC subscale scores. Thus, WOMAC total score ranges from 0 to 300 with 0 being the best and 300 being the worst. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated post-Baseline timepoint. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
Change From Baseline in the WOMAC Pain Subscale Score at Weeks 1, 2 and 3
The pain subscale of the WOMAC questionnaire consisted of 5 questions related to severity of pain experienced by the participant when walking, stair climbing, at night, at rest, weightbearing, on average, during the last 48 hours. Participants scored the questions on a 5-point Likert scale ranging from 0 to 4 daily using eDiary where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The total pain subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items in dimension)\*5. Higher scores indicated more pain. Change from Baseline was calculated by subtracting the Baseline normalized WOMAC pain subscale score from the normalized score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
Change From Baseline in the WOMAC Stiffness Subscale Score at Weeks 1, 2 and 3
The stiffness subscale of the WOMAC questionnaire consisted of 2 questions related to severity of stiffness experienced by the participant at morning and during the day, on average, during the last 48 hours. Participants scored the questions on a 5-point Likert scale with scores ranging from 0 to 4 daily using eDiary, where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The total stiffness subscale score for was normalized on a 0 to 100 scale calculated as = (sum of raw score items in dimension)\*12.5. Higher scores indicated more stiffness. Change from Baseline was calculated by subtracting the Baseline normalized WOMAC stiffness subscale score from the normalized score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 1, Week 2 and Week 3
Change From Baseline in Sleep/Alertness Assessed Using Karolinska Sleepiness Scale (KSS) at Days 7, 14 and 21
KSS measured the subjective level of sleepiness/alertness during the day. Participants rated how sleepy or alert they were feeling using KSS with scores ranging from 1 to 9 where 1 = extremely alert, 2 = very alert, 3 = alert, 4 = fairly alert, 5 = neither alert nor sleepy, 6 = some signs of sleepiness, 7 = sleepy, but no efforts to keep alert, 8 = sleepy, some efforts to keep alert, 9 = very sleepy, great effort to keep alert, fighting sleep. Higher scores indicated greater sleepiness. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.
Time frame: Baseline, Day 7, Day 14, and Day 21
Change From Baseline in Health-related QoL Assessed Using EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire at Days 7, 14, and 21
Health-related QoL of participants was assessed using the EQ-5D-5L questionnaire. It consisted of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) with 5 response levels for each dimension where Level 1 = no problems, Level 2 = slight problems, Level 3 = moderate problems, Level 4 = severe problems, Level 5 = unable to perform activities/extreme problems. Participants were asked to indicate their health by ticking the box next to the most appropriate response level for each dimension. The response levels were used to derive a health index score based on the Crosswalk Value Set for the United States ranging from less than 0 (worst imaginable health) to 1 (best imaginable health) where higher scores indicated better health. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated timepoint. Baseline was defined as Day 0. A positive change from Baseline indicated improvement.
Time frame: Baseline, Days 7, 14 and 21
This study was conducted at 2 centers in the United States (US) and 6 centers in the European Union (EU) (Poland).
| Milestone | Voltaren Gel |
|---|---|
| Started | 196 |
| Completed | 194 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Sponsors' decision | 1 |
The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A mixed model with repeated measures (MMRM) was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 1. Baseline value was calculated as the sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement. Modified Intent-To-Treat (mITT) population included all participants who met the inclusion/exclusion criteria, who used study product at least once and had data from at least one post Baseline quality of life (QoL) questionnaire to support at least one of the secondary endpoint assessments.
| minutes | Voltaren Gel |
|---|---|
| Baseline | 249.2 ± 92.99 |
| Change from Baseline at Week 1 | 14.2 ± 53.54 |
The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A MMRM was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 2. Baseline value was calculated as sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.
| minutes | Voltaren Gel |
|---|---|
| Baseline | 249.2 ± 92.99 |
| Change from Baseline at Week 2 | 10.7 ± 60.93 |
The average minutes of MVPA were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on physical activity. A MMRM was used to analyse the change from Baseline in MVPA average minutes. Change from Baseline was calculated by subtracting the Baseline average MVPA value from the average MVPA value at Week 3. Baseline value was calculated as sum of minutes of MVPA over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.
| minutes | Voltaren Gel |
|---|---|
| Baseline | 249.2 ± 92.99 |
| Change from Baseline at Week 3 | -0.8 ± 71.08 |
Daily average number of steps taken were measured through a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on functional mobility. MMRM was used to analyse the change from Baseline in daily average number of steps taken. Change from Baseline was calculated by subtracting the average number of steps taken at Baseline from the average number of steps taken at each indicated post-Baseline timepoint. Baseline value was calculated as the sum of steps taken over the Baseline period divided by duration of Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.
| steps | Voltaren Gel |
|---|---|
| Baseline | 13826.5 ± 5076.05 |
| Change from Baseline at Week 1 | 602.3 ± 2930.69 |
| Change from Baseline at Week 2 | 323.1 ± 3515.66 |
| Change from Baseline at Week 3 | -57.1 ± 3826.57 |
Sedentary/non-sedentary time was measured using a connected activity tracker (Actigraph device) worn by the participants to evaluate the effects of Voltaren Gel on functional mobility. Ratio of sedentary/non-sedentary time was calculated as = Total number of minutes defined as sedentary behaviour divided by Total number of non-sedentary behaviour minutes where number of non-sedentary behaviour minutes in the day was derived as the sum of light activity and MVPA. Change from Baseline was calculated by subtracting the Baseline ratio of sedentary/non-sedentary time from the ratio at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.
| ratio | Voltaren Gel |
|---|---|
| Baseline | 1.984 ± 1.1595 |
| Change from Baseline at Week 1 | -0.028 ± 0.5376 |
| Change from Baseline at Week 2 | 0.003 ± 0.5571 |
| Change from Baseline at Week 3 | 0.089 ± 0.6121 |
Gait was assessed through speed and step irregularity measured via cadence using a connected activity tracker (Actigraph device) worn by the participants. Change from Baseline was calculated as by subtracting the average cadence at Baseline from the cadence at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.
| steps per minute | Voltaren Gel |
|---|---|
| Baseline | 109.207 ± 6.8045 |
| Change from Baseline at Week 1 | -0.149 ± 6.3135 |
| Change from Baseline at Week 2 | -1.126 ± 11.7981 |
| Change from Baseline at Week 3 | -1.751 ± 14.7336 |
Gait was assessed through speed and step irregularity measured via gait speed using a connected activity tracker (Actigraph device) worn by the participants. Change from Baseline was calculated by subtracting the average gait speed at Baseline from the Average gait speed at each indicated post-Baseline timepoint. Baseline was defined as the number of non-missing days between Day -6 and Day 0. A positive change from Baseline indicated improvement.
| meters per second | Voltaren Gel |
|---|---|
| Baseline | 1.010 ± 0.1385 |
| Change from Baseline at Week 1 | -0.007 ± 0.0809 |
| Change from Baseline at Week 2 | -0.016 ± 0.1069 |
| Change from Baseline at Week 3 | -0.016 ± 0.1401 |
Indices of morning stiffness were assessed through levels of mobility 30 minutes post-wake. Functional mobility was measured through a connected activity tracker (Actigraph device) worn by the participants. Daily morning stiffness 30 minutes post-wake was defined as the total vector magnitude counts from Actigraph device 30 minutes post-wake. Change from Baseline was calculated as = (Average morning stiffness 30 minutes post-wake at each indicated post-Baseline timepoint minus Average Baseline morning stiffness 30 minutes post-wake). Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.
| vector magnitude counts | Voltaren Gel |
|---|---|
| Baseline | 75593.364 ± 44958.5420 |
| Change from Baseline at Week 1 | 1969.758 ± 28283.0182 |
| Change from Baseline at Week 2 | 2332.422 ± 28420.8109 |
| Change from Baseline at Week 3 | -1893.342 ± 34458.1863 |
Indices of morning stiffness were assessed through levels of mobility 60 minutes post-wake. Functional mobility was measured through a connected activity tracker (Actigraph device) worn by the participants. Daily morning stiffness 60 minutes post-wake was defined as the total vector magnitude counts from Actigraph device 60 minutes post-wake. Change from Baseline was calculated as = (Average morning stiffness 60 minutes post-wake at each indicated post-Baseline timepoint minus Average Baseline morning stiffness 30 minutes post-wake). Baseline was defined as the number of non-missing days between Day -6 and Day 0. A negative change from Baseline indicated improvement.
| vector magnitude counts | Voltaren Gel |
|---|---|
| Baseline | 149034.401 ± 86661.4977 |
| Change from Baseline at Week 1 | 2891.276 ± 45249.4973 |
| Change from Baseline at Week 2 | 2438.403 ± 48859.7477 |
| Change from Baseline at Week 3 | -6734.944 ± 54957.9211 |
Participants completed the WOMAC questionnaire daily using eDiary. The WOMAC questionnaire consisted of 24 questions categorised in 3 subscales - Pain, Stiffness, Physical function. The physical function subscale consisted of 17 questions related to level of difficulty in performing functions, on average, during the last 48 hours scored on a 5-point Likert scale with scores ranging from 0 to 4, where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. Total WOMAC physical function subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items)\*1.47. Higher scores indicated more difficulty in performing physical functions. Change from Baseline was calculated by subtracting the normalized WOMAC subscale score at Baseline from the normalized WOMAC subscale score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.
| score on a scale | Voltaren Gel |
|---|---|
| Baseline | 48.702 ± 12.9284 |
| Change from Baseline at Week 1 | -8.677 ± 12.6188 |
| Change from Baseline at Week 2 | -11.926 ± 14.0764 |
| Change from Baseline at Week 3 | -15.644 ± 16.9641 |
The average minutes of MVPA on each day were measured through a connected activity tracker (Actigraph device) worn by the participants to assess the functional mobility. Baseline was calculated as the average of MVPA values collected during the Baseline period, where Baseline period was the number of non-missing days between Day -6 and Day 0.
| minutes | Voltaren Gel |
|---|---|
| Baseline | 249.2 ± 92.99 |
| Day 1 | 274.1 ± 119.79 |
| Day 2 | 268.4 ± 124.96 |
| Day 3 | 259.3 ± 124.79 |
| Day 4 | 270.8 ± 126.09 |
| Day 5 | 255.8 ± 115.05 |
| Day 6 | 255.1 ± 119.03 |
| Day 7 | 260.4 ± 112.45 |
| Day 8 | 264.2 ± 122.21 |
| Day 9 | 258.0 ± 126.33 |
| Day 10 | 266.5 ± 128.05 |
| Day 11 | 262.9 ± 124.18 |
| Day 12 | 252.0 ± 122.99 |
| Day 13 | 261.3 ± 122.89 |
| Day 14 | 254.3 ± 114.00 |
| Day 15 | 254.6 ± 124.49 |
| Day 16 | 250.3 ± 114.15 |
| Day 17 | 251.1 ± 122.16 |
| Day 18 | 253.8 ± 124.67 |
| Day 19 | 239.1 ± 118.63 |
| Day 20 | 244.0 ± 120.81 |
| Day 21 | 107.8 ± 85.88 |
Physical function subscale score of the WOMAC questionnaire was used to study participant's perceived ability to exercise more regularly. It consisted of 17 questions related to the level of difficulty in performing functions, on average, during the last 48 hours scored on a 5-point Likert scale with scores ranging from 0 to 4, daily using eDiary where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. Total WOMAC physical function subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items)\*1.47. Higher scores indicated more difficulty in performing physical functions.
| score on a scale | Voltaren Gel |
|---|---|
| Week 1 | 40.375 ± 14.7527 |
| Week 2 | 37.072 ± 15.9130 |
| Week 3 | 32.781 ± 17.2916 |
Participants rated the pain intensity experienced by them daily within the eDiary, using NRS. NRS is an 11-point scale with scores ranging from 0 to 10 where score 0 = no pain, 1 = slight pain, 2-3 = mild pain, 4-6 = moderate pain, 7 = severe pain, 8 to 9 = extreme pain, 10=pain as bad as it could be. Higher scores indicated greater pain intensity. Change from Baseline was calculated by subtracting the Baseline NRS score from the NRS score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.
| score on a scale | Voltaren Gel |
|---|---|
| Baseline | 5.7 ± 1.31 |
| Change from Baseline at Week 1 | -1.5 ± 1.54 |
| Change from Baseline at Week 2 | -1.9 ± 1.69 |
| Change from Baseline at Week 3 | -2.6 ± 1.96 |
Participants completed the WOMAC questionnaire daily. The WOMAC questionnaire consisted of 24 questions each scored on a 5-point scale: 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The WOMAC questionnaire was categorized in 3 subscales - Pain (5 questions, score ranges 0-20), Stiffness (2 questions, score ranges 0-8), Physical function (17 questions, score ranges 0-68). Each subscale score was normalized on a 0 to 100 scale calculated as: Pain subscale score= (sum of raw score items in dimension)\*5; Stiffness subscale score= (sum of raw score items in dimension)\*12.5; Physical function subscale score= (sum of raw score items in dimension)\*1.47. WOMAC Total score = sum of the 3 normalized WOMAC subscale scores. Thus, WOMAC total score ranges from 0 to 300 with 0 being the best and 300 being the worst. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated post-Baseline timepoint. A negative change from Baseline indicated improvement.
| score on a scale | Voltaren Gel |
|---|---|
| Baseline | 147.040 ± 38.1349 |
| Change from Baseline at Week 1 | -27.359 ± 38.7623 |
| Change from Baseline at Week 2 | -36.062 ± 42.4964 |
| Change from Baseline at Week 3 | -47.852 ± 49.4526 |
The pain subscale of the WOMAC questionnaire consisted of 5 questions related to severity of pain experienced by the participant when walking, stair climbing, at night, at rest, weightbearing, on average, during the last 48 hours. Participants scored the questions on a 5-point Likert scale ranging from 0 to 4 daily using eDiary where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The total pain subscale score was normalized on a 0 to 100 scale calculated as = (sum of raw score items in dimension)\*5. Higher scores indicated more pain. Change from Baseline was calculated by subtracting the Baseline normalized WOMAC pain subscale score from the normalized score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.
| score on a scale | Voltaren Gel |
|---|---|
| Baseline | 48.196 ± 13.2952 |
| Change from Baseline at Week 1 | -9.458 ± 13.7044 |
| Change from Baseline at Week 2 | -12.422 ± 14.5893 |
| Change from Baseline at Week 3 | -16.383 ± 16.6274 |
The stiffness subscale of the WOMAC questionnaire consisted of 2 questions related to severity of stiffness experienced by the participant at morning and during the day, on average, during the last 48 hours. Participants scored the questions on a 5-point Likert scale with scores ranging from 0 to 4 daily using eDiary, where score 0=none, 1=slight, 2=moderate, 3=severe, 4=extreme. The total stiffness subscale score for was normalized on a 0 to 100 scale calculated as = (sum of raw score items in dimension)\*12.5. Higher scores indicated more stiffness. Change from Baseline was calculated by subtracting the Baseline normalized WOMAC stiffness subscale score from the normalized score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.
| score on a scale | Voltaren Gel |
|---|---|
| Baseline | 50.142 ± 16.7965 |
| Change from Baseline at Week 1 | -9.242 ± 18.6173 |
| Change from Baseline at Week 2 | -11.719 ± 19.2063 |
| Change from Baseline at Week 3 | -15.680 ± 20.6853 |
KSS measured the subjective level of sleepiness/alertness during the day. Participants rated how sleepy or alert they were feeling using KSS with scores ranging from 1 to 9 where 1 = extremely alert, 2 = very alert, 3 = alert, 4 = fairly alert, 5 = neither alert nor sleepy, 6 = some signs of sleepiness, 7 = sleepy, but no efforts to keep alert, 8 = sleepy, some efforts to keep alert, 9 = very sleepy, great effort to keep alert, fighting sleep. Higher scores indicated greater sleepiness. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated post-Baseline timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement.
| score on a scale | Voltaren Gel |
|---|---|
| Baseline | 3.9 ± 1.60 |
| Change from Baseline at Day 7 | -0.2 ± 1.56 |
| Change from Baseline at Day 14 | -0.2 ± 1.70 |
| Change from Baseline at Day 21 | -0.4 ± 1.66 |
Health-related QoL of participants was assessed using the EQ-5D-5L questionnaire. It consisted of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) with 5 response levels for each dimension where Level 1 = no problems, Level 2 = slight problems, Level 3 = moderate problems, Level 4 = severe problems, Level 5 = unable to perform activities/extreme problems. Participants were asked to indicate their health by ticking the box next to the most appropriate response level for each dimension. The response levels were used to derive a health index score based on the Crosswalk Value Set for the United States ranging from less than 0 (worst imaginable health) to 1 (best imaginable health) where higher scores indicated better health. Change from Baseline was calculated by subtracting the Baseline score from score at each indicated timepoint. Baseline was defined as Day 0. A positive change from Baseline indicated improvement.
| score on a scale | Voltaren Gel |
|---|---|
| Baseline | 0.67 ± 0.124 |
| Change from Baseline at Day 7 | 0.04 ± 0.098 |
| Change from Baseline at Day 14 | 0.05 ± 0.097 |
| Change from Baseline at Day 21 | 0.07 ± 0.111 |
Collected over From signing of informed consent form up to end of study (up to approximately 28 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voltaren Gel | 0/196 (0%) | 0/196 (0%) | 17/196 (8.7%) |
| Event | Voltaren Gel |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/196 |
| HeadacheNervous system disorders | 3/196 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/196 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/196 |
| Ear infectionInfections and infestations | 1/196 |
| SinusitisInfections and infestations | 1/196 |
| Viral infectionInfections and infestations | 1/196 |
| Viral upper respiratory tract infectionInfections and infestations | 1/196 |
| ErythemaSkin and subcutaneous tissue disorders | 1/196 |
| RashSkin and subcutaneous tissue disorders | 1/196 |
The enrolled population included all participants who met the inclusion/exclusion criteria as recorded on the 'Participant Eligibility: Inclusion/Exclusion Criteria' electronic case report form (eCRF) page.
| Age, Continuous(years) | Voltaren Gel |
|---|---|
| Mean | 61.8 ± 9.33 |
| Sex: Female, Male(Participants) | Voltaren Gel |
|---|---|
| Female | 118 |
| Male | 78 |
| Race (NIH/OMB)(Participants) | Voltaren Gel |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 188 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Voltaren Gel |
|---|---|
| Hispanic or Latino | 19 |
| Not Hispanic or Latino | 20 |
| Missing | 157 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
Ran from Apr 2024 to primary completion in Oct 2024, 6 months.
Results were first posted in Jan 2026, 1 year 2 months after primary completion.
Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diclofenac Sodium Gel